Cannabinoids for skin diseases and hair regrowth. (7th August 2021)

• Record Type: Journal Article
• Authors: Gupta, Aditya K.; Talukder, Mesbah
• Is Part Of: Journal of cosmetic dermatology. Volume 20:Number 9(2021)
• Page Start: 2703
• Page End: 2711
• Publication Date: 2021-08-07
• Subjects: cannabidiol -- cannabinoids -- endocannabinoid system -- hair growth -- skin diseases; Skin -- Diseases -- Treatment -- Periodicals; Lasers in surgery -- Periodicals; Skin -- Pathophysiology -- Periodicals; Surgery, Plastic -- Periodicals; 616.5
• DOI: 10.1111/jocd.14352
• Languages: English
• ISSNs: 1473-2130

Abstract

Abstract: The use of cannabis for skin diseases and hair regrowth is at the preliminary stage. Legalization: Many countries have approved cannabis for medical use; however, four countries Canada, Uruguay, South Africa, and Georgia have legalized it for both medical and recreational purposes. The endocannabinoid system: The endocannabinoid system may maintain skin homeostasis; two notable endocannabinoids include 2‐Arachidonoylglycerol (2‐AG) and N ‐arachidonoylethanolamine (AEA). Routes of administration and pharmacokinetics: Topical cannabinoids can avoid the first‐pass metabolism and reduce respiratory side effects; however, the high hydrophobicity of cannabinoids may hinder percutaneous absorption. Skin disorders and hair growth: Human clinical studies suggest that cannabinoids may be used in eczema, acne, pruritus, and systemic sclerosis treatment. Cannabidiol (CBD) may enhance hair growth via multiple mechanisms. Safety: Topical cannabis may cause mild side effects such as pruritus, burning, erythema, and stinging; they are relatively safer than inhalation and oral cannabis. Cannabis use may be associated with allergic symptoms and reduced immune response to live vaccination. Cannabinoids in practice: Despite growing interest, dermatologists should be cautious prescribing cannabinoids due to insufficient clinical data on both efficacy and safety.